Cargando…
Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials
Protein kinases (PKs) have emerged as one of the most intensively investigated drug targets in current pharmacological research, with indications ranging from oncology to neurodegeneration. Tau protein hyperphosphorylation was the first pathological post-translational modification of tau protein des...
Autores principales: | Basheer, Neha, Smolek, Tomáš, Hassan, Imtaiyaz, Liu, Fei, Iqbal, Khalid, Zilka, Norbert, Novak, Petr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611587/ https://www.ncbi.nlm.nih.gov/pubmed/37264120 http://dx.doi.org/10.1038/s41380-023-02113-z |
Ejemplares similares
-
Hyperphosphorylation-Induced Tau Oligomers
por: Iqbal, Khalid, et al.
Publicado: (2013) -
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
por: Kontsekova, Eva, et al.
Publicado: (2014) -
Enriched environment ameliorates propagation of tau pathology and improves cognition in rat model of tauopathy
por: Mate, Veronika, et al.
Publicado: (2022) -
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
por: Pascoal, T A, et al.
Publicado: (2017) -
Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice
por: Dai, Chun-ling, et al.
Publicado: (2018)